URGN Stock Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.
UroGen Pharma Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.32|
|52 Week High||US$12.63|
|52 Week Low||US$4.85|
|1 Month Change||-30.44%|
|3 Month Change||11.68%|
|1 Year Change||-31.18%|
|3 Year Change||-73.65%|
|5 Year Change||-78.45%|
|Change since IPO||-40.49%|
Recent News & Updates
UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth PlansMar 09
We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn RateNov 04
Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?Jun 14
What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their EstimatesMay 18
What Type Of Returns Would UroGen Pharma's(NASDAQ:URGN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?Mar 15
We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth CarefullyFeb 17
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-TermJan 27
How Much Of UroGen Pharma Ltd. (NASDAQ:URGN) Do Insiders Own?Jan 06
President Elizabeth Barrett Just Bought 4.6% More Shares In UroGen Pharma Ltd. (NASDAQ:URGN)Dec 16
UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years.Dec 08
|URGN||US Biotechs||US Market|
Return vs Industry: URGN underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: URGN underperformed the US Market which returned -20.5% over the past year.
|URGN Average Weekly Movement||10.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: URGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: URGN's weekly volatility (11%) has been stable over the past year.
About the Company
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
UroGen Pharma Ltd. Fundamentals Summary
|URGN fundamental statistics|
Is URGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|URGN income statement (TTM)|
|Cost of Revenue||US$6.98m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.74|
|Net Profit Margin||-175.16%|
How did URGN perform over the long term?See historical performance and comparison